Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Olfactory deficits a biomarker of Alzheimer’s disease?

April 22, 2015

…eriod, 36.4% of aMCI patients with impaired olfaction developed AD, compared to 17.3% of aMCI patients with intact olfaction. The ROC AUC for conversion to AD was 0.62, which the authors noted is comparable to CSF biomarkers such as beta-amyloid42, tau and p-tau. Thus, impaired olfaction may be an easily administered, low-cost tool for stratifying the risk of conversion from aMCI to AD. Guest Reviewer: Dr. Daniel Selchen, Head of Neurology, St. Mi…

From Framingham to Facebook: the contagion of controversy

April 1, 2015

…Human Services Policy for the Protection of Human Research Subjects. Editor-in-Chief Inder Verma acknowledged that as a private company, Facebook was under no obligation to conform to the HHS provisions, so the journal decided that it could proceed with publication. “It is nevertheless a matter of concern that the collection of the data by Facebook may have involved practices that were not fully consistent with the principles of obtaining informed…

Optimizing patient assessment in MS: NEDA and beyond

March 12, 2015

…ange to determine the proportion of patients that achieved disease activity-free (DAF) status, defined as no relapses, no sustained disability progression and no MRI activity (no Gd+ lesions, no new/enlarging T2 lesions) (Havrdova et al. Lancet Neurol 2009;8:254-260). DAF was sometimes mischaracterized as “disease-free”, and subsequently acquired the designation of “no evidence of disease activity” (NEDA). To date, two-year NEDA rates have been re…

Passive immunotherapies in AD: new data from AAIC

February 4, 2015

…ab (Cummings J. Alzheimer Association International Conference; abstract 04-11-06). A total of 433 patients with mild to moderate AD were randomized to one of two doses of crenezumab (300 mg SC q2wks or 15 mg/kg q4wks) or placebo for 68 weeks. There was no benefit on cognitive decline or global function with either active regimen. However, in the subgroup with milder AD, there was a 35.4% reduction in cognitive decline and a 19.6% reduction in glo…

Pharma sales projected to top $1 trillion

February 4, 2015

…en: If anyone doubted that multiple sclerosis is among other things a multibillion dollar industry – doubt no more! It is interesting to note that all three MS drugs in the top 20 most valuable R&D projects are injectable. One is a beta interferon that appears (there are no head-to-head data) to have efficacy similar to the established agents but has much less frequent injections. Ocrelizumab was very efficacious in phase II trials and has large p…